Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Revenue

Halozyme Therapeutics had revenue of $290.08M in the quarter ending September 30, 2024, with 34.28% growth. This brings the company's revenue in the last twelve months to $947.36M, up 21.35% year-over-year. In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth.

• Revenue (ttm): $947.36M
• Revenue Growth: +21.35%
• P/S Ratio: 8.02
• Revenue / Employee: $2,539,826
• Employees: 373
• Market Cap: 7.58B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	829.25M	169.14M	25.62%
Dec 31, 2022	660.12M	216.81M	48.91%
Dec 31, 2021	443.31M	175.72M	65.67%
Dec 31, 2020	267.59M	71.60M	36.53%
Dec 31, 2019	195.99M	44.13M	29.06%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.